Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Thoracic 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 6Melanoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Lymphoma 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thymoma 1Neoplasms 1Neoplasm Metastasis 1Microsatellite Instability 1Mesothelioma 1Glioblastoma 1Extensive Stage Small Cell Lung Carcinoma 1Esophageal Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 3Paclitaxel 3Nivolumab 2Drug Therapy 2Bevacizumab 2Azacitidine 2vocimagene amiretrorepvec 1ulixertinib 1spartalizumab 1sacituzumab govitecan 1ruxolitinib 1rucaparib 1regorafenib 1pazopanib 1motexafin gadolinium 1fludarabine 1erythromycin propionate-N-acetylcysteinate 1epacadostat 1depatuxizumab mafodotin 1cobimetinib 1cediranib 1cc-486 1carboxyamido-triazole 1capmatinib 1bemcentinib 1aflibercept 1abiraterone 1abemaciclib 1Uncertainty 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × epacadostat × Thoracic × Clear all
NCT02327078 2025-08-14

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Incyte Corporation

Phase 1/2 Completed
307 enrolled 27 charts
CNSDermatologicGastrointestinalGynecologicHead & NeckLymphoidThoracic

Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡